Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse Expanding Patient Population to Include Pediatric Patients

Firdapse is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ( " Catalyst " ) (Nasdaq: CPRX), a commercial-stage...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news